A phase II study of dose‐dense and dose‐intense ABVD (ABVDDD‐DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma
Authors:
- 27 March 2014
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 166 (1) , 118-129
Abstract
Summary: We explored activity and safety of a dose‐dense/dose‐intense adriamycin, bleomycin, vinblastine and dacarbazine regimen (ABVDDD‐DI) in 82 patients with advanced Hodgkin Lymphoma. Patients entered a two‐stage Bryant‐Day Phase II study to receive six cycles of ABVDDD‐DI without consolidation radiotherapy. Cycles were supported with granulocyte colony‐stimulating factor and delivered every 21 d; drugs were administered on days 1 and 11 at the same doses of standard ABVD except for doxorubicin (35 mg/m2; first four cycles only). Co‐primary endpoints were complete response (CR) rate and severe acute cardiopulmonary toxicity; secondary endpoints were event‐free (EFS) and disease‐free survival (DFS). All patients received the four doxorubicin‐intensified courses and 96% concluded all six cycles (82·3% within the intended 18 weeks). This translated into a 66·9% increase of received dose‐intensity for doxorubicin and 31·8% for the other agents over standard ABVD. The CR rate was 95·1% (78/82) and 87·8% (72/82) achieved a metabolic CR after two cycles. Cardiopulmonary toxicity never exceeded grade 2 and affected 14·6% of patients. Most frequent toxicities were grade 4 neutropenia (10%) and anaemia (9%), grade 3 infection (17%) and grade 2 mucocutaneous changes (30%). Five‐year EFS and DFS was 88·3% and 93·7%, respectively. ABVDDD‐DI regimen was well‐tolerated and ensured substantial CR and EFS rates without radiotherapy.Keywords
This publication has 64 references indexed in Scilit:
- BEACOPPescalated versus ABVD in advanced Hodgkin's lymphomaThe Lancet Oncology, 2013
- ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 TrialsJournal of Clinical Oncology, 2013
- Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin LymphomaBlood, 2012
- State of the art in the treatment of Hodgkin lymphomaNature Reviews Clinical Oncology, 2012
- Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study GroupJournal of Clinical Oncology, 2011
- Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphomaAnnals of Oncology, 2009
- ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factorsAnnals of Oncology, 2007
- Involved-Field Radiotherapy for Advanced Hodgkin's LymphomaNew England Journal of Medicine, 2003
- The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA PerspectiveThe Journal of Clinical Pharmacology, 2003
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDNew England Journal of Medicine, 1992